Summary
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
History
Sonnet BioTherapeutics was founded in 2016 by Dr. Rajan Sankaran and a team of researchers from Stanford University. Since its inception, the company has focused on developing treatments for metabolic diseases, such as type 2 diabetes, and making them more accessible to people in need around the world.
Mission
Sonnet BioTherapeutics’ mission is to create innovative treatments for a variety of metabolic diseases and make those treatments more accessible to everybody, particularly those in underserved communities.
Vision
Sonnet BioTherapeutics’ vision is to become the premier specialty diabetic health and biotechnology company that provides groundbreaking therapies to patients in need around the world.
Key Team
Mr. Donald J. Griffith CPA, CPA (Controller & Director)
Dr. Richard T. Kenney FACP, M.D. (Chief Medical Officer)
Ms. Susan Dexter (Chief Technical Officer)
Mr. Manuel Dafonseca (Head of Clinical Operations)
Recognition and Awards
Sonnet BioTherapeutics has won several awards for its research and development efforts. In 2019, the company was recognized as one of the Most Innovative Biotech Companies by FierceBiotech and was awarded the Rising Star award by Frost & Sullivan.
References
